Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia
Identifieur interne : 005282 ( Main/Merge ); précédent : 005281; suivant : 005283Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia
Auteurs : Inger Marie Skogseid [Norvège] ; Jo R Islien [Norvège] ; Bj Rgulf Claussen [Norvège] ; Emilia Kerty [Norvège]Source :
- Movement disorders [ 0885-3185 ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
We examined the impact of cervical dystonia (CD) and long-term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long-term treatment were obtained from 62 CD patients aged 31-66 years (median. 53 years: 61% females) who had been treated for a median of 5 years (range, 1.5-10 years). The employment rate fell from 84% at the onset of CD to 47% before initiation of BTX treatment. With long-term BTX treatment, 72% of those who worked at the initiation of treatment stayed employed, and 67% of those on sick leave returned to work. A younger age and a higher level of education increased the probability of being employed and avoiding disability benefits. Among those who were younger than 55 years at evaluation of BTX treatment (n = 40), the employment rate increased from 47% to 65% with treatment, and among the male patients, it reached the level of the general population (86%). About half of the 34% who received disability benefits did so already before the BTX treatment was initiated.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001C32
- to stream PascalFrancis, to step Curation: 001089
- to stream PascalFrancis, to step Checkpoint: 001E04
Links to Exploration step
Pascal:06-0191527Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia</title>
<author><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Oslo and Department of Neurology, Rikshospitalet University Hospital</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Oslo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biostatistics, Rikshospitalet University Hospital</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Oslo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institute of General Practice and Community Medicine, University of Oslo</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Oslo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Oslo and Department of Neurology, Rikshospitalet University Hospital</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Oslo</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0191527</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 06-0191527 INIST</idno>
<idno type="RBID">Pascal:06-0191527</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C32</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001089</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001E04</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Skogseid I:long:term:botulinum</idno>
<idno type="wicri:Area/Main/Merge">005282</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia</title>
<author><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Oslo and Department of Neurology, Rikshospitalet University Hospital</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Oslo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biostatistics, Rikshospitalet University Hospital</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Oslo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institute of General Practice and Community Medicine, University of Oslo</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Oslo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Oslo and Department of Neurology, Rikshospitalet University Hospital</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Oslo</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Dystonia</term>
<term>Human</term>
<term>Long term</term>
<term>Nervous system diseases</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Dystonie</term>
<term>Long terme</term>
<term>Bontoxilysin</term>
<term>Traitement</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We examined the impact of cervical dystonia (CD) and long-term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long-term treatment were obtained from 62 CD patients aged 31-66 years (median. 53 years: 61% females) who had been treated for a median of 5 years (range, 1.5-10 years). The employment rate fell from 84% at the onset of CD to 47% before initiation of BTX treatment. With long-term BTX treatment, 72% of those who worked at the initiation of treatment stayed employed, and 67% of those on sick leave returned to work. A younger age and a higher level of education increased the probability of being employed and avoiding disability benefits. Among those who were younger than 55 years at evaluation of BTX treatment (n = 40), the employment rate increased from 47% to 65% with treatment, and among the male patients, it reached the level of the general population (86%). About half of the 34% who received disability benefits did so already before the BTX treatment was initiated.</div>
</front>
</TEI>
<affiliations><list><country><li>Norvège</li>
</country>
</list>
<tree><country name="Norvège"><noRegion><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name>
</noRegion>
<name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name>
<name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name>
<name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005282 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005282 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= Pascal:06-0191527 |texte= Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |